Methemoglobinemia associated with dapsone treatment in solid organ transplant recipients: a two-case report and review.
Dapsone, a sulfone antibiotic, has been increasingly used in solid-organ transplant recipients for the primary prevention of Pneumocystis carinii pneumonia, especially in patients with documented sulfa allergy. A known side effect of dapsone therapy, however, is methemoglobinemia, a condition leading to impaired tissue oxygen delivery. This report documents two cases of dapsone-induced methemoglobinemia in patients after solid organ transplantation with emphasis on the importance of clinical recognition and benefits of treatment. Further, the pathophysiology and causes of this condition are extensively reviewed.
Plotkin
J S
JS
Department of Anesthesiology, University of Maryland Medical Center, Baltimore 21201-1595, USA.
Buell
J F
JF
Njoku
M J
MJ
Wilson
S
S
Kuo
P C
PC
Bartlett
S T
ST
Howell
C
C
Johnson
L B
LB
D000368:Aged; D003622:Dapsone / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016030:Kidney Transplantation; D016031:Liver Transplantation; D008708:Methemoglobinemia / Q000139:chemically induced*; D008875:Middle Aged; D016377:Organ Transplantation; D016035:Pancreas Transplantation; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*
D003622:Dapsone